2-甲基-2-[4-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)-苯基]-丙腈 | 1082066-30-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-2-[4-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)-苯基]-丙腈
• 英文名称: 2-methyl-2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]propionitrile
• 英文别名: 2-Methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanenitrile；2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanenitrile
• CAS: 1082066-30-5
• 化学式: C₁₆H₂₂BNO₂
• 分子量: 271.167
• InChiKey: XJOJSFBFKRCJTK-UHFFFAOYSA-N

物化性质

• 沸点：
  384.1±25.0 °C(Predicted)
• 密度：
  1.02±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.79
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-甲基-2-[4-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)-苯基]-丙腈 在 盐酸 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium carbonate 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 7.5h， 生成 2-(4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-6-fluoroquinolin-4-yl)phenyl)-2-methylpropanenitrile trifluoroacetate
  参考文献：
  名称：

  Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity

  摘要：

  Aldehyde dehydrogenases (ALDHs) are responsible for the metabolism of aldehydes (exogenous and endogenous) and possess vital physiological and toxicological functions in areas such as CNS, inflammation, metabolic disorders, and cancers. Overexpression of certain ALDHs (e.g., ALDHIAI) is an important biomarker in cancers and cancer stem cells (CSCs) indicating the potential need for the identification and development of small molecule ALDH inhibitors. Herein, a newly designed series of quinoline-based analogs of ALDH1A1 inhibitors is described. Extensive medicinal chemistry optimization and biological characterization led to the identification of analogs with significantly improved enzymatic and cellular ALDH inhibition. Selected analogs, e.g., 86 (NCT-505) and 91 (NCT-506), demonstrated target engagement in a cellular thermal shift assay (CETSA), inhibited the formation of 3D spheroid cultures of OV-90 cancer cells, and potentiated the cytotoxicity of paclitaxel in SKOV-3-TR, a paclitaxel resistant ovarian cancer cell line. Lead compounds also exhibit high specificity over other ALDH isozymes and unrelated dehydrogenases. The in vitro ADME profiles and pharmacokinetic evaluation of selected analogs are also highlighted.

  DOI：

  10.1021/acs.jmedchem.8b00270
• 作为产物：
  描述：

  2-(4-溴苯基)-2-甲基丙腈 、 联硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.5h， 生成 2-甲基-2-[4-(4,4,5,5-四甲基-[1,3,2]二噁硼烷-2-基)-苯基]-丙腈
  参考文献：
  名称：

  Syk 억제제

  摘要：

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.

  公开号：

  KR20160037198A

文献信息

• [EN] COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS ET PROCÉDÉS D'UTILISATION DESDITS COMPOSÉS
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2018098499A1

  公开（公告）日：2018-05-31

  The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

  本发明部分涉及融合的杂环化合物和组合物，用于预防和/或治疗与电压门控钠离子通道异常功能相关的疾病或症状，例如异常的晚期/持续性钠电流。本文还提供了治疗与钠离子通道异常功能相关的疾病或症状，包括德拉维特综合征或癫痫的方法。
• PHENYL-TRIAZOLO-PYRIDINE COMPOUNDS
  申请人：Eli Lilly and Company

  公开号：US20170029420A1

  公开（公告）日：2017-02-02

  The present invention provides a compound of the Formula (I) below: wherein R 1 is selected from the group consisting of H, CH 3 , CN, —CH 2 CN, —C(CH 3 ) 2 CN, F, Cl, and Br; R 2 is selected from the group consisting of H, —O(C1-C 3 alkylene)R4, —CH 2 CN, CN, —OCH 3 , CF 2 , —C(CH 3 ) 2 CN, —C(CH 3 ) 2 , —S(O) 2 CH 3 , —S(O) 2 NH 2 , and —OCF 2 ; R 3 is selected from the group consisting of H, CH3, and —OCH 3 ; and R 4 is selected from the group consisting of H, —C(CH 3 ) 2 CN, —OCH 3 , —S(O) 2 CH 3 , CN, and —C(CH 3 ) 2 OH; or a pharmaceutical salt thereof, methods of treating type two diabetes using the compound and a process for preparing the compound.

  本发明提供了以下式（I）的化合物：其中R1选自H、CH3、CN、—CH2CN、—C(CH3)2CN、F、Cl和Br组成的群；R2选自H、—O（C1-C3烷基）R4、—CH2CN、CN、—OCH3、CF2、—C(CH3)2CN、—C(CH3)2、—S(O)2CH3、—S(O)2NH2和—OCF2组成的群；R3选自H、CH3和—OCH3；R4选自H、—C(CH3)2CN、—OCH3、—S(O)2CH3、CN和—C(CH3)2OH组成的群；或其药用盐，使用该化合物治疗二型糖尿病的方法以及制备该化合物的方法。
• Syk 억제제
  申请人：GILEAD SCIENCES, INC. 길리애드 사이언시즈, 인코포레이티드(519990290219)

  公开号：KR20160037198A

  公开（公告）日：2016-04-05

  본 개시내용은 Syk 억제제인 화합물, 및 암 및 염증성 상태를 비롯한 다양한 질환 상태의 치료에서의 그의 용도에 관한 것이다. 특정한 실시양태에서, 화합물의 구조는 하기 화학식 I로 주어진다. 003c#화학식 I003e# 상기 식에서, X, X, X, R, R, R, R, 및 Y는 본원에 기재된 바와 같다. 본 개시내용은 화학식 I의 화합물 또는 그의 제약상 허용되는 염을 포함하는 제약 조성물, 및 Syk에 의해 매개되는 상태를 치료하기 위해 이들 화합물 및 조성물을 사용하는 방법을 추가로 제공한다.

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.
• ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS
  申请人：ELI LILLY AND COMPANY

  公开号：US20160333005A1

  公开（公告）日：2016-11-17

  The present invention provides a compound of the Formula (I) below: Wherein R 1 is selected from the group consisting of H, CH 3 , CN, CH 2 CN, C(CH 3 ) 2 CN, and F; R 2 is selected from the group consisting of H, O(C 1 -C 3 alkyl)R 5 , CH 2 CN, and CN; R 3 is selected from the group consisting of H, OCH 3 , CN, C(CH 3 ) 2 CN, and CH2CN; R 4 is selected from the group consisting of H and CH 3 ; R 5 is selected from the group consisting of H, CN, C(CH 3 ) 2 CN, OCH 3 , S(O) 2 CH 3 , and C(CH 3 ) 2 OH; provided that at least one selected from the group consisting of R1, R2, R3 and R4 is H; or a pharmaceutically acceptable salt thereof, methods of treating diabetes using the compound and a process for preparing the compound.

  本发明提供了以下式（I）的化合物：其中R1选择自H、CH3、CN、CH2CN、C(CH3)2CN和F组成的群体中；R2选择自H、O(C1-C3烷基)R5、CH2CN和CN组成的群体中；R3选择自H、OCH3、CN、C(CH3)2CN和CH2CN组成的群体中；R4选择自H和CH3组成的群体中；R5选择自H、CN、C(CH3)2CN、OCH3、S(O)2CH3和C(CH3)2OH组成的群体中；至少选择自R1、R2、R3和R4中的一个为H；或其药学上可接受的盐，使用该化合物治疗糖尿病的方法以及制备该化合物的过程。
• [EN] PHENYL-TRIAZOLO-PYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS PHÉNYL-TRIAZOLO-PYRIDINE
  申请人：LILLY CO ELI

  公开号：WO2015105786A1

  公开（公告）日：2015-07-16

  The present invention provides a compound of the Formula (I) below: wherein R1 is selected from the group consisting of H, CH3, CN, -CH2CN, -C(CH3)2CN, F, Cl, and Br; R2 is selected from the group consisting of H, -O(C1-C3alkylene)R4, -CH2CN, CN, - OCH3, CF2, -C(CH3)2CN, -C(CH3)2, -S(O)2CH3, -S(O)2NH2, and -OCF2; R3 is selected from the group consisting of H, CH3, and -OCH3; and R4 is selected from the group consisting of H, -C(CH3)2CN, -OCH3, -S(O)2CH3, CN, and -C(CH3)2OH; or a pharmaceutical salt thereof, methods of treating type two diabetes using the compound and a process for preparing the compound.

  本发明提供了以下式（I）的化合物：其中R1选自H、CH3、CN、-CH2CN、-C（CH3）2CN、F、Cl和Br组成的群体；R2选自H、-O（C1-C3烷基）R4、-CH2CN、CN、-OCH3、CF2、-C（CH3）2CN、-C（CH3）2、-S（O）2CH3、-S（O）2NH2和-OCF2组成的群体；R3选自H、CH3和-OCH3组成的群体；R4选自H、-C（CH3）2CN、-OCH3、-S（O）2CH3、CN和-C（CH3）2OH组成的群体；或其药用盐，使用该化合物治疗二型糖尿病的方法以及制备该化合物的过程。